GH Research PLC - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GHRS Nasdaq 2836 www.ghres.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GH Research PLC

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - May 18th, 2026 8:03 am
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - May 16th, 2026 2:12 pm
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update - May 14th, 2026 5:00 am
GH Research Announces Pricing of $117.5 Million Underwritten Offering - Apr 29th, 2026 6:00 am
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. - Apr 24th, 2026 2:12 pm
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain - Apr 24th, 2026 8:19 am
‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar - Apr 22nd, 2026 6:49 am
How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying - Apr 20th, 2026 2:26 pm
Sector Update: Health Care Stocks Fall Late Afternoon - Apr 20th, 2026 1:55 pm
Market Feels Weak, But Stocks Tell Stories - Apr 20th, 2026 12:34 pm
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness - Apr 20th, 2026 7:00 am
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness - Apr 20th, 2026 5:23 am
Psychedelic stocks soar after Trump signs executive order to fast-track treatments - Apr 20th, 2026 3:53 am
Trump Trade: President to sign order on psychedelic used for PTSD - Apr 17th, 2026 3:56 pm
Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation - Apr 4th, 2026 8:06 am
Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.? - Apr 2nd, 2026 9:31 am
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD - Mar 25th, 2026 9:10 am
What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say? - Mar 24th, 2026 11:34 pm
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Mar 6th, 2026 8:15 am
GH Research Reports Full Year 2025 Financial Results and Provides Business Update - Mar 5th, 2026 5:00 am